Close
American Drug Delivery & Formulation Summit
Xylem

Production & Manufacturing

Continuous Manufacturing Reshaping Drug Formulation

Continuous manufacturing drug formulation represents the most significant leap in pharmaceutical engineering in over a century, fundamentally altering how medications are conceived, developed, and delivered to the global market. For decades, the industry operated under the batch manufacturing paradigm,...

Shilpa Biologicals Launches PartnerPower Platform for CDMOs

Shilpa Biologicals Pvt. Ltd. (SBPL) has introduced PartnerPower Platform, a proprietary digital transparency solution designed to provide global sponsors with continuous, real-time visibility across biologics development and manufacturing activities. Announced on 22 June 2026 from Dharwad, India, the platform...

Alzheimerโ€™s Drug Packaging Expansion Receives UK Funding

Eisai is moving ahead with a major upgrade of its manufacturing facility in Hatfield, Hertfordshire, backed by support from the United Kingdomโ€™s Life Sciences Innovative Manufacturing Fund (LSIMF). The Japanese drugmaker is investing approximately 48 million pounds sterling ($64.5...

Recipharm Investment Expands US Sterile Manufacturing

Recipharm has unveiled a multi-million-dollar investment in its US operations aimed at increasing sterile fill and finish manufacturing capacity for biologics and advanced therapies. The expansion comes after the company secured a clinical biologics fill and finish agreement with...

MGS Advances Healthcare Product Development with Hybrid Tooling

MGS, a healthcare-focused contract development and manufacturing organization, has expanded its Hybrid Tooling capability worldwide after successfully deploying the approach alongside its A.i.r. Platformโ„ข. The company said the broader rollout is intended to help healthcare manufacturers accelerate product development,...

Daewoong and Chime Biologics Partner for Biosimilar Push

Chime Biologics and Daewoong Pharmaceutical have entered into a strategic collaboration to develop and manufacture a dupilumab biosimilar candidate referencing Dupixent for global markets. The partnership, announced by VMS Group, combines the development and manufacturing capabilities of Chime Biologics...

Aragen Backs Renaissance Rare Disease Therapy Launch

Contract research, development, and manufacturing organization (CRDMO) Aragen has announced the successful production of the first commercial-scale GMP batches of Daretabart (hu1418K322A), the lead therapeutic candidate of UK-based Renaissance Pharma Limited. The milestone marks a key step forward in...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป